

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36 (Cancelled).

37 (Withdrawn/Currently Amended). The method of claim ~~36~~43, wherein said ~~agent-peptide~~ peptide is a peptide (b), the sequence of which is comprised within the sequence of S-Ag, ~~wherein said agent is~~ selected from the group consisting of the peptides:

TSSEVATE (SEQ ID NO:4);

DTNLASST (SEQ ID NO:6);

DTNLASSTIIKEGIDKT (SEQ ID NO:8);

VPLLANNRERRGIALDGKIKHE (SEQ ID NO:9);

TSSEVATEVPFRLMHPQPED (SEQ ID NO:10);

SLTKTLTLVPLLANNRERRG (SEQ ID NO:11);

SLTRTLTLLPLLANNRERAG (SEQ ID NO:12);

KEGIDKTVMGILVSYQIKVKL (SEQ ID NO:13); and

KEGIDRTVLGILVSYQIKVKL (SEQ ID NO:14).

38-39 (Cancelled).

40 (Withdrawn/Currently Amended). The method of claim ~~39~~43, wherein said non-autoimmune eye disease, disorder or injury is blunt trauma caused by an agency selected from

the group consisting of a foreign body, contusion, laceration, burn or laser surgery.

41 (Withdrawn/Currently Amended). The method of claim ~~39~~43, wherein said non-autoimmune eye disease, disorder or injury is selected from the group consisting of a conjunctival, a corneal, a retinal, and an optic nerve or optic pathway disorder.

42 (Currently Amended). The method of claim ~~39~~43, wherein said non-autoimmune eye disease, disorder or injury is glaucoma.

43 (New). A method for treating a disease, disorder or injury in the eye, wherein said disease, disorder or injury is other than an autoimmune disease of the eye, the method comprising immunizing an individual having such a disease, disorder or injury with:

(a) a peptide within the sequence of the pathogenic self-antigen S-Ag which is associated with the T-cell-mediated eye-specific autoimmune disease uveitis, the peptide being selected from the group consisting of:

TSSEVATE	(SEQ ID NO:4);
DTNLASST	(SEQ ID NO:6);
DTNLASSTIIKEGIDKTV	(SEQ ID NO:8);
VPLLANNRERRGIALDGKIKHE	(SEQ ID NO:9);
TSSEVATEVPFRLMHPQPED	(SEQ ID NO:10);

Appln. No. 10/509,180
Amdt. dated March 21, 2008
Reply to Office action of September 21, 2007

SLTKTLTLVPLLANNRERRG (SEQ ID NO:11);
SLTRTLTLLPLLANNRERAG (SEQ ID NO:12);
KEGIDKTVMGILVSYQIKVKL (SEQ ID NO:13); and
KEGIDRTVLGILVSYQIKVKL (SEQ ID NO:14); or

(b) a peptide obtained by modification of the
peptide of (a), selected from the group consisting of the
peptides:

TSSEAATE (SEQ ID NO:5); and
DTALASST (SEQ ID NO:7),

whereby the administration of an effective amount of
said peptide is effective for treatment of said disease,
disorder or injury in the eye.